CPCB-RPE1

CPCB-RPE1 is a bioengineered, ultrathin implant composed of a monolayer of human embryonic stem cell-derived retinal pigmented epithelium (hESC-RPE) cells seeded onto a synthetic parylene substrate. The implant is designed to replace damaged or lost RPE cells in the retina, specifically for patients with advanced dry age-related macular degeneration (AMD), particularly the geographic atrophy subtype. The healthy RPE cells on the patch are intended to promote survival and function of adjacent retinal cells by replacing dystrophic or nonfunctional native RPE, thereby potentially improving visual function. The product is surgically implanted into the subretinal space as an outpatient procedure. Developed by Regenerative Patch Technologies in collaboration with academic institutions including California Institute of Technology, University of Southern California, and University of California Santa Barbara, CPCB-RPE1 has completed Phase 1/2 trials and is currently being evaluated in Phase 2b clinical studies for safety and efficacy in geographic atrophy[1][6][8][9].

Other names

Embryonic stem cell therapy (Regenerative Patch Technologies)hESC-derived RPE cell coated parylene membrane implant